NCT05208944 2026-04-14
THIO Sequenced With Cemiplimab in Advanced NSCLC
Maia Biotechnology
Phase 2 Recruiting
Clinical Trials
58 trialsNCT02864992 2026-04-13
VISION
EMD Serono
Phase 2 Active not recruiting
NCT05968326 2026-04-13
IMCODE003
Genentech, Inc.
Phase 2 Recruiting
NCT05063565 2026-03-27
ROWAN
Boston Scientific Corporation
Phase 2 Active not recruiting
NCT07259317 2026-03-27
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Corcept Therapeutics
Phase 2 Recruiting
NCT07332000 2026-03-20
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
Candel Therapeutics, Inc.
Phase 2 Recruiting
NCT04379596 2026-02-23
DG-03
AstraZeneca
Phase 2 Recruiting
NCT05935748 2025-11-12
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
NiKang Therapeutics, Inc.
Phase 2 Terminated
NCT04363801 2025-10-09
DisTinGuish
Leap Therapeutics, Inc.
Phase 2 Terminated
NCT04646005 2025-09-08
Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
Regeneron Pharmaceuticals
Phase 2 Completed
NCT05577715 2025-09-04
A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)
Bristol-Myers Squibb
Phase 2 Terminated
NCT06038578 2025-08-03
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
Toray Industries, Inc
Phase 2 Recruiting
NCT06942767 2025-04-27
Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Qilu Pharmaceutical Co., Ltd.
Phase 2 Not yet recruiting
NCT04989816 2024-11-21
DG-06
AstraZeneca
Phase 2 Completed
NCT01318642 2024-11-08
Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas
NantBioScience, Inc.
Phase 2 Terminated
NCT06636682 2024-10-21
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
Cellvax Therapeutics Inc
Phase 2 Recruiting
NCT03664024 2024-08-22
KEYNOTE-782
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03329690 2022-03-18
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]
Daiichi Sankyo
Phase 2 Completed
NCT02387216 2021-10-12
SHERLOC
Elevation Oncology
Phase 2 Terminated
NCT00667862 2021-06-21
Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer
Novartis
Phase 2 Completed
NCT01002924 2021-04-08
Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)
Endocyte
Phase 2 Completed
NCT01577654 2021-04-01
TARGET
Endocyte
Phase 2 Completed
NCT01616303 2020-09-14
A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer
Quest PharmaTech Inc.
Phase 2 Completed
NCT01413087 2019-11-01
LAPC-BC-819
Anchiano Therapeutics Israel Ltd.
Phase 2 Terminated
NCT01111604 2019-08-06
A Study of Ramucirumab or Icrucumab in Colorectal Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01233375 2019-03-11
Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma
Clovis Oncology, Inc.
Phase 2 Completed
NCT00215644 2018-11-02
MATRIX EG
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT02875340 2018-10-15
A Study of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
ValiSeek Limited
Phase 2 Completed
NCT00252382 2018-09-24
Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC
Sunesis Pharmaceuticals
Phase 2 Completed
NCT02195180 2018-07-27
Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma
ERYtech Pharma
Phase 2 Completed
NCT02119676 2018-02-13
Study of Ruxolitinib in Colorectal Cancer Patients
Incyte Corporation
Phase 2 Terminated
NCT00725712 2017-08-24
Study of GSK1363089 in Metastatic Gastric Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00632203 2017-06-07
Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146)
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT01431391 2017-05-30
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
Dendreon
Phase 2 Completed
NCT00719264 2017-03-20
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
Novartis
Phase 2 Completed
NCT01640847 2017-02-07
MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases
Imunon
Phase 2 Withdrawn
NCT00154388 2016-11-18
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Phase 2 Completed
NCT00813605 2016-10-27
QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
NantCell, Inc.
Phase 2 Completed
NCT00688753 2016-09-02
MACS0460
Novartis
Phase 2 Completed
NCT01433263 2016-03-02
Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas
Novartis
Phase 2 Completed
NCT00998322 2015-04-10
A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma
Oncolytics Biotech
Phase 2 Completed
NCT02310971 2015-04-03
Cvac as Maintenance Treatment Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas
Prima BioMed Ltd
Phase 2 Withdrawn
NCT00511485 2015-02-27
Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)
Endocyte
Phase 2 Completed
NCT01301612 2014-07-14
Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS)
Eurofarma Laboratorios S.A.
Phase 2 Withdrawn
NCT01124786 2014-04-17
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)
Clovis Oncology, Inc.
Phase 2 Completed
NCT00600821 2013-11-08
A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.
Pfizer
Phase 2 Completed
NCT01830322 2013-08-14
Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer
Cornerstone Pharmaceuticals
Phase 2 Withdrawn
NCT00083278 2012-04-27
Study of MDX-010 in Stage IV Breast Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT00813072 2012-03-02
Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
PharmaEngine
Phase 2 Completed
NCT00117351 2011-02-17
VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features
Millennium Pharmaceuticals, Inc.
Phase 2 Terminated